Investigating how to inhibit a specific cancer-causing mutation in KRAS.
KRAS G12C: Kinetic and Redox Characterization of Covalent Inhibition
This study is looking at new ways to block a specific cancer mutation called KRAS G12C, which is often found in lung cancer, to help create better treatments for patients dealing with this condition.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Univ of North Carolina Chapel Hill NIH-funded |
| Lab location | 1 site (Chapel Hill, United States) |
| Project ID | NIH-11031289 on NIH RePORTER |
What this research studies
This research focuses on understanding how to effectively inhibit the KRAS G12C mutation, which is commonly found in various cancers, particularly non-small cell lung cancer. The team will use a novel fluorescence-based method to study how different inhibitors interact with this mutation, aiming to uncover the kinetic mechanisms that influence their effectiveness. By examining the redox sensitivity of the KRAS G12C protein, the research seeks to provide insights that could enhance the design of targeted therapies for patients with this mutation.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with non-small cell lung cancer harboring the KRAS G12C mutation.
Not a fit: Patients without KRAS mutations or those with other types of cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatments for patients with KRAS G12C mutations, potentially enhancing their response to existing therapies.
How similar studies have performed: Other research has shown promising results with similar approaches to targeting KRAS mutations, particularly with the recent FDA approval of specific inhibitors.
Where this research is happening
Chapel Hill, United States
- Univ of North Carolina Chapel Hill — Chapel Hill, United States (Active)
Researchers
- Principal investigator: Campbell, Sharon L — Univ of North Carolina Chapel Hill
- Study coordinator: Campbell, Sharon L
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.